Truist downgraded Doximity (DOCS) to Hold from Buy with a price target of $29, down from $37. The firm has a taken a more cautious outlook on Doximity, saying its revenue growth visibility has softened and structural risks are mounting. There is limited clarity on pharma digital marketing budgets, the analyst tells investors in a research note. Truist believes Doximity’s fiscal 2027 growth profile will likely be below consensus while it faces emerging competitive pressure from AI-native platforms such as OpenEvidence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity downgraded to Hold from Buy at Truist
- Doximity announces resignation of CFO Anna Bryson, reaffirms Q4, FY guidance
- Doximity price target lowered to $47 from $56 at BofA
- Doximity price target lowered to $30 from $38 at KeyBanc
- Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls